Ph D in Immunology from Harvard University
Master of Medical Sciences degree from Harvard Medical School
Bachelor of Sciences degree from Cornell University
EMBA degree from CKGSB – Chungkong Graduate School of Business in China
Dr. Karen Liu is a founding partner of 3E Bioventures Capital, a fund that focuses on venture investments in healthcare related sectors, such as drug, device, diagnostics, increasingly, interdisciplinary innovations at the frontier of BT (Biotech) and IT (information technology). While 3E primarily invests in China, it is also actively exploring cross-border investment opportunities with China angle or can leverage China advantages.
Dr. Karen Liu has been active in China healthcare venture investment since 2006. Her past investments include device companies such as Reach Surgical, Sinomed, diagnostic companies such as Biochain, Micropoint, BGI, drug related companies such as Chiral Quest, Shenogen and mobile health company such as Apricot Forest. Prior to 3E Bioventures, Karen was a partner at Kaiwu Capital in charge of healthcare investment from 2011-2015 and before that, was Managing Director at CRCI Capital from 2007-2011, also in charge of healthcare investment.
In 2006, Karen co-founded Shenogen Pharma, a company developing innovative liver cancer therapeutics, and was its first angle investor. From 2000-2004, she was an entrepreneur and senior team member of 3721, an Internet search company founded by Internet veteran Hongyi Zhou. She helped build up the small internet company and achieved profitability and eventually sold it to Yahoo in early 2004. Karen Liu also worked as a consultant at McKinsey & Company from 1998-2000.